Royalty Pharma (RPRX) Cash from Investing Activities (2019 - 2026)

Royalty Pharma has reported Cash from Investing Activities for 8 years, with the latest figure at -$477.9 million in Q1 2026.

• Quarterly Cash from Investing Activities fell 194.83% year-over-year to -$477.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.6 billion (down 24.35% YoY) and the FY2025 annual result came in at -$1.6 billion, up 39.73% from the prior year.
• Cash from Investing Activities rose to -$477.9 million in Q1 2026 per RPRX's latest filing, from -$847.8 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $503.9 million in Q1 2025 and troughed at -$1.4 billion in Q3 2022.
• A 5-year average of -$463.1 million and a median of -$477.9 million in 2026 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2023 and 2025: Cash from Investing Activities plunged 5102.47% in 2023, then surged 681.55% in 2025.
• Over 5 years, Cash from Investing Activities stood at $414.7 million in 2022, then tumbled by 341.16% to -$1.0 billion in 2023, then soared by 49.45% to -$505.6 million in 2024, then sank by 67.69% to -$847.8 million in 2025, then jumped by 43.63% to -$477.9 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered -$477.9 million, -$847.8 million, and -$958.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.